DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells

Trial Profile

DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Eribulin (Primary) ; Everolimus (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms DETECT-IV
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Trial design for three trials (DETECT III, DETECT IV and DETECT V) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jan 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 400 to 520.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top